NovaBiotics nears licensing deal for topical antifungal candidate
This article was originally published in Scrip
Executive Summary
The UK biotechnology company NovaBiotics is shortly to complete a Phase IIa trial of its topical fungal nail infection treatment, Novexatin (NP213).